Altuviiio Market Report 2026

Altuviiio Market Overview

• The Altuviiio market growth in the historic period has been driven by dependence on standard factor viii therapies, high bleeding episode burden • Market expansion is supported by demand for long acting therapies, expansion of prophylaxis guidelines • Growth Driver: Growing Hemophilia Prevalence Drives Market Growth • Market Trend: Sanofi's FDA Approval Of ALTUVIIIO A Breakthrough In Hemophilia A Treatment • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Altuviiio Market?

Altuviiio is the brand name for efanesoctocog alfa, an advanced therapeutic product for treating hemophilia A, a hereditary bleeding disorder caused by a deficiency of clotting factor VIII. It is designed to provide extended protection against bleeding by requiring less frequent dosing compared to traditional factor VIII therapies, improving convenience for patients. The main types of indications in altuviiio are hemophilia A, prophylaxis treatment, and on-demand treatment. Hemophilia A is a genetic disorder where the blood doesn't clot properly due to a lack of clotting factor VIII. It is distributed through various channels, such as hospital pharmacies and specialty pharmacies, for various end users, including adults, geriatrics, and pediatrics.

What Is The Altuviiio Market Growth Forecast?

The growth in the forecast period can be attributed to demand for long acting therapies, expansion of prophylaxis guidelines, pediatric treatment uptake, innovation in clotting factor engineering, improved reimbursement coverage. Major trends in the forecast period include shift toward extended half-life factor therapies, reduced injection frequency in hemophilia care, improved patient adherence and quality of life, expansion of prophylactic treatment adoption, rising preference for advanced recombinant factors.

Global Altuviiio Market Segmentation

1) By Indication: Hemophilia A, Prophylaxis Treatment, On-Demand Treatment 2) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies 3) By End Use: Adult, Geriatric, Pediatric

What Is The Driver Of The Altuviiio Market?

The growing prevalence of hemophilia is expected to propel the growth of the altuviiio market going forward. Hemophilia refers to a rare genetic bleeding disorder in which the blood does not clot properly due to a deficiency or absence of clotting factors. The growing prevalence of hemophilia is driven by improved diagnosis and treatment advancements that enhance detection and extend life expectancy. Altuviiio is used in hemophilia A to replace missing factor VIII, controlling bleeding episodes with an extended half-life for less frequent dosing. For instance, in July 2025, according to the National Blood Authority, an Australia-based blood management agency, there were 2,788 patients living with hereditary haemophilia A (HMA) in 2023–2024, up from 2,681 patients in 2022–2023. Therefore, the growing prevalence of hemophilia is driving the growth of the altuviiio industry.

Key Players In The Global Altuviiio Market

Major companies operating in the altuviiio market are Swedish Orphan Biovitrum

Global Altuviiio Market Trends and Insights

Major companies operating in the altuviiio market are focusing on developing advanced therapies, such as extended half-life factor replacements, to boost protection, enhance patient quality of life, and reduce treatment burden. Extended half-life factor replacements refer to engineered clotting factors designed to remain active in the bloodstream significantly longer than standard factors, enabling fewer infusions to prevent bleeding episodes. For instance, in February 2023, Sanofi SA, a France-based pharmaceutical industry company, received FDA approval of ALTUVIIIO, a pioneering once-weekly therapy for hemophilia A, which marks a significant advancement in treatment options for patients. This new class of factor VIII therapy significantly enhances bleed protection by maintaining normal to near-normal factor activity levels with a single weekly dose. Utilizing innovative Fc fusion technology, ALTUVIIIO offers a longer half-life compared to traditional therapies, resulting in a substantial reduction in bleeding episodes, as evidenced by clinical trials showing a mean annualized bleeding rate of 0.70. This approval, which follows several designations including Breakthrough Therapy and Fast Track, represents a major advancement in hemophilia management, promising improved quality of life for patients.

What Are Latest Mergers And Acquisitions In The Altuviiio Market?

In February 2023, Sanofi SA, a France-based pharmaceutical industry company, partnered with Swedish Orphan Biovitrum. This collaboration aims to develop and commercialize innovative hemophilia treatments, including Alprolix, Elocta/Eloctate, and Altuviiio, to improve patient outcomes and expand global access to life-changing therapies for rare blood disorders. Swedish Orphan Biovitrum is a Sweden-based pharmaceutical company that.

Regional Insights

North America was the largest region in the altuviiio market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Altuviiio Market?

The altuviiio market consists of sales of products including adynovate, advate, kovaltry, and jivi. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Altuviiio Market Report 2026?

The altuviiio market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the altuviiio industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.